Bionova Scientific opens pDNA facility in the US
The CDMO’s new site will support its work in cell and gene therapy.
List view / Grid view
The CDMO’s new site will support its work in cell and gene therapy.
Late-stage trials in Sjögren’s disease and primary immune thrombocytopenia met primary endpoints.
Amid intensifying market competition, the next-generation therapies could shape the future of oncology.
CBER head makes surprise comeback just weeks after his abrupt resignation.
The pharma company’s digital innovation efforts also progress with the opening of a new Hyderabad facility.
The scheme will provide more support and a streamlined application process to companies constructing new US facilities.
Amid shifting global dynamics, continued resilience in UK healthcare M&A deal activity is expected in H2 2025, forecasting predicts.
The European Commission hopes its planned legislation will enable biotechnology companies to bring products from laboratory to market more quickly.
Regulatory pressures and demand for trained operators is expected to hinder growth of the rapid microbiological testing market into the next decade, research suggests.
HHS throws out Pfizer, CSL Seqirus and Sanofi proposals, and will restructure AstraZeneca and Moderna projects.
The novel approach could reduce the industry’s reliance on fossil fuels by offering a sustainable production alternative for pharmaceuticals.
New digital initiative will support the pharma company’s manufacturing and supply chain ambitions.
The trial is the first pivotal clinical programme to have met the standard of complete scalp hair regrowth, suggesting potential in immune-mediated diseases.
The deal between the two European CDMOs expands Ofichem’s Nordic biotech footprint and drug substance capabilities.
The proposed transaction means Just-Evotec Biologics’ Toulouse site would be used to develop and manufacture Sandoz biosimilars.